Piramal Healthcare part of Piramal group today said it has received approval from European regulator to market its bio-orthopaedic product BST- CarGel used for cartilage repair in the European Union.
"The current European approval provides access to a $200 million-market in Europe with a potential for a larger market with greater penetration of treatment in Europe," Piramal Group Chairman Ajay Piramal said.
The approval will serve as the basis to obtain commercial authorisation for the product in other geographic areas such West Asia, Asia Pacific region, South America and other countries including India, Piramal Healthcare said in a filing to BSE.
"The company plans to launch the BST-CarGel for commercial sale in the fourth quarter of the 2012 calendar year after completing user studies with key opinion leaders," it added.
Piramal Healthcare had acquired assets relating to BST-CarGel from Canada based BioSyntech Technologies Inc in 2010, the company said.
BST-CarGel is a European Union class III medical device, Piramal Healthcare said.
Scrips of Piramal Healthcare were today trading at Rs 453 per share in the afternoon trade on BSE, down 1.01% from its previous close.
You’ve hit your limit of 5 free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app